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Abstract
Background: The IL4-590 gene polymorphism has been shown to be associated with elevated levels of
anti-Plasmodium falciparum IgG antibodies and parasite intensity in the malaria protected Fulani of West
Africa. This study aimed to investigate the possible impact of IL4-590C/T polymorphism on anti-P.
falciparum IgG subclasses and IgE antibodies levels and the alteration of malaria severity in complicated and
uncomplicated malaria patients with or without previous malaria experiences.
Methods: Anti-P.falciparum IgG subclasses and IgE antibodies in plasma of complicated and uncomplicated
malaria patients with or without previous malaria experiences were analysed using ELISA. IL4-590
polymorphisms were genotyped using RFLP-PCR. Statistical analyses of the IgG subclass levels were done
by Oneway ANOVA. Genotype differences were tested by Chi-squared test.
Results: The IL4-590T allele was significantly associated with anti-P. falciparum IgG3 antibody levels in
patients with complicated (P = 0.031), but not with uncomplicated malaria (P = 0.622). Complicated malaria
patients with previous malaria experiences carrying IL4-590TT genotype had significantly lower levels of
anti-P. falciparum IgG3 (P  = 0.0156), while uncomplicated malaria patients with previous malaria
experiences carrying the same genotype had significantly higher levels (P = 0.0206) compared to their IL4-
590 counterparts. The different anti-P. falciparum IgG1 and IgG3 levels among IL4 genotypes were
observed. Complicated malaria patients with previous malaria experiences tended to have lower IgG3
levels in individuals carrying TT when compared to CT genotypes (P = 0.075). In contrast, complicated
malaria patients without previous malaria experiences carrying CC genotype had significantly higher anti-
P. falciparum IgG1 than those carrying either CT or TT genotypes (P = 0.004, P = 0.002, respectively).
Conclusion: The results suggest that IL4-590C or T alleles participated differently in the regulation of
anti-malarial antibody isotype profiles in primary and secondary malaria infection and, therefore, could play
an important role in alteration of malaria severity.
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Background
Anti-Plasmodium falciparum specific antibodies play a crit-
ical role in immune protection against asexual blood
stages of the parasite, in which anti-P. falciparum IgG anti-
bodies involved in reducing severity of the disease [1]. In
particular, the cytophilic IgG1 and IgG3 subclasses are
considered to protect against P. falciparum, whereas IgG2
and IgM are not, and even suggested to block protective
effects of the former Ig subclasses [2]. Anti-P. falciparum
IgE, as well as total IgE antibodies, which are elevated in
individuals exposed to malaria in Thailand, have been
implicated to play a pathogenic role during malaria infec-
tion [1]. In contrast, the anti-P. falciparum IgE levels in
asymptomatic individuals in Tanzania were associated
with a reduced risk for subsequent malaria disease [3].
The regulation of antibody profiles in patients with com-
plicated and uncomplicated malaria is still largely
unknown. In both human and mice, different cytokines
are thought to induce particular Ig isotypes. In humans,
IL4 regulates B cells to express the γ1, γ2, γ3, γ4, α1, α2 and
ε, germline gene transcripts (GLT) and to secrete the cor-
responding proteins [4-6]. IL10 promotes isotype switch-
ing from IgM to IgG1, IgG3, IgG4 and/or IgE [7-9] while
IFN-γ promotes IgG2 [10,11]. The inter-individual varia-
tion in cytokine production may be reflected by polymor-
phisms in regulatory region of the corresponding genes.
The IL4-590 C/T transition in IL4 promoter was shown to
influence the IL4 production as well as the elevated levels
of total IgE [12,13]. The IL4-590T allele corresponded to
IL4-524T and IL4-589T alleles in an alternative number-
ing scheme [14-16]. In the Fulani tribe in West Africa, IL4-
524T allele was found to be associated with the elevated
levels of anti-P. falciparum IgG antibodies and protection
against malaria [14], while IL4-589T allele was associated
with the elevated levels of total IgE in children with severe
malaria living in Burkina Faso [15]. Conversely, total IgE
levels were significantly elevated in children with cerebral
malaria who carried IL4-590T allele and have been living
in Ghana [16]. Thus, the role of IL4-590T allele in regulat-
ing antibody profiles and malaria severity is controversial.
In mice infected with Plasmodium chabaudi chabaudi, the
specific IgG2a and IgG3 antibodies are predominant in
primary polyclonal B cell activation. At that point, IFN-γ is
markedly stimulated, while IL4 is moderately enhanced.
In secondary IgG1-restricted response, only IL4 is pro-
duced [17]. According to previous findings, the IL4-590
C/T polymorphism influences the balance between IL4
and IFN-γ and thus, could alter the severity of malaria
[18]. When the same sets of sera were used subsequently
to determine the anti-P. falciparum IgG subclasses and IgE
antibodies, the results showed different regulation in
patients with complicated and uncomplicated malaria
[19].
Therefore, it is of interest to evaluate the impact of IL4-590
C/T single nucleotide polymorphism (SNP) on the pro-
duction of anti-P. falciparum -IgG1, -IgG2, -IgG3, IgE anti-
bodies and to determine whether such polymorphism
and specific antibodies levels were associated with previ-
ous malaria experiences and clinical outcome of the dis-




The same sets of patients previously reported were studied
[18,19]. Briefly, 110 and 169 patients with complicated
(CM) and uncomplicated malaria (UCM), respectively,
who had been living at Thai-Myanmar border in the west
and Thai-Cambodia border in the east of Thailand; where
malaria is endemic; were enrolled. These areas are consid-
ered as having low and seasonal malaria transmission.
The annual malaria incidence rates in 2001 were 2 to 6/
1,000 population [20]. The two groups of patients were
matched for age (P  = 0.849), gender (P  = 0.137) and
nationality,  i.e  Thai, Burmese, Mon and Karen (P  =
0.614). The median age was 25 years (ranged 14-67) for
complicated and 24 years (ranged 13-65) for uncompli-
cated malaria. Based on the interview and clinical records,
27.3% of patients with complicated and 55% of those
with uncomplicated malaria had previous malaria experi-
ences. The number of previous malaria episodes in these
patients varied widely, describing mostly 1-2 episodes of
malaria (84/125), 3-8 episodes (27/125) and many epi-
sodes (12/125). However, the duration of malaria infec-
tion upon admission and the previous malaria episodes
among patients were far different, varying from one
month to more than 10 years (mostly between one month
and two years). However, both groups of patients had
acute malaria infection upon admission. Therefore, com-
plicated malaria patients with or without previous malaria
experiences (CME, CMN, respectively) and uncompli-
cated malaria patients with or without previous malaria
experiences (UCME, UCMN, respectively) were identified.
Clinical manifestations of complicated and uncompli-
cated malaria were defined according to World Health
Organization criteria [21]. Cerebral malaria was defined
as unrousable coma with positive asexual forms of P. fal-
ciparum in blood smears, while other causes of coma were
excluded. Severe malaria but not cerebral (non-cerebral
severe malaria) was defined as patients exhibiting one or
more of the following signs, hyperparasitaemia
(>250,000 parasite/ml), hypoglycaemia (glucose <22
nmol/l), severe anaemia (haematocrit <20% or haemo-
globin <7.0 g/d) or increased serum level of creatinine
more than 3.0 mg/dl. The patients with complicated
malaria comprised of all severe forms including cerebral
malaria. Uncomplicated malaria was characterized by a
positive blood smear and fever without other causes ofMalaria Journal 2009, 8:286 http://www.malariajournal.com/content/8/1/286
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infections and no manifestations of severe malaria as
described. The patients were transported for admission to
the Hospital for Tropical Diseases, Faculty of Tropical
Medicine, Mahidol University, Bangkok. The study has
been ethically approved by the Institute Review Board of
the Faculty of Tropical Medicine, Mahidol University,
Bangkok and the fully informed consent was obtained
from all patients. Other details about the patients are
delineated in Table 1.
Blood samples
Blood samples from patients with complicated and
uncomplicated malaria were collected in EDTA sterile
tubes before treatment on admission. The plasma and
packed cells were separated and frozen at -20°C until use.
Microscopic examination
Thick and thin films were made for microscopic examina-
tion after standard Giemsa staining. Parasite densities
were determined by calculating P. falciparum parasites per
ml of blood obtained from the number of parasites
observed per 1,000 erythrocytes in thin film or per 200
leucocytes in thick film.
Malaria antigens
The laboratory P. falciparum strain F32 was used to pre-
pare the antigens for malaria antibodies detection. The
late stages of P. falciparum infected erythrocytes were
enriched by 60% Percoll and sonicated as described [22].
Detection of anti-P. falciparum IgG subclasses and IgE 
antibody levels
Anti-P. falciparum -IgG1, -IgG2, -IgG3 and IgE antibodies
levels were determined by enzyme-linked immunosorb-
ent assay (ELISA) as described previously [23] with some
modification. The monoclonal antibodies used in the
ELISA were given [19]. Negative control sera were from
Swedish donors who have never been exposed to malaria.
Genotyping
DNA was extracted from buffy coats by phenol-chloro-
form extraction [24]. Genomic DNA was used as a tem-
plate for amplification by PCR and IL4-590 C/T
polymorphism was detected by restriction fragment
length polymorphism analysis as previously described
[18].
Statistical analyses
The data were analysed using SPSS or StatView computer
software. The differences in characteristics of the patients
with complicated and uncomplicated malaria were ana-
lyzed by unpaired t-test or Mann Whitney U  test. The
highest fever, haemoglobin, creatinine, and glucose levels
between the two patient groups were tested by unpaired t-
test, while the other characteristics were tested by Mann
Whitney U test. The Chi-squared test was used to compare
allele and genotype frequencies between the two patients
groups. One-way ANOVA and unpaired t-test after log
transformation were used to evaluate the significant asso-
ciations between anti-P. falciparum IgG subclasses or IgE
antibodies and the IL4-590 genotypes. The IgG subclasses
and IgE were taken in the extreme 3 tiles. The genetic dis-
tribution of the IL4-590 genotypes between the low and
high quartile was compared using Chi-squared test. A P-
value of less than 0.05 was considered to be significant.
Results
IL4-590 C/T allele frequency in complicated and 
uncomplicated malaria patients with or without previous 
malaria experiences
As described previously [19], the frequency of IL4-590 T
allele in patients with complicated malaria did not differ
from those with uncomplicated malaria (0.72 in both
groups). When the allele and genotype frequencies in
patients with or without previous malaria experiences
were explored, the allele and genotype frequencies
between complicated and uncomplicated malaria groups
either with or without previous malaria experiences did
not differed (P-value allele: 0.7501 vs 0.8755 and geno-
type: 0.9137 vs 0.9459 for patients with or without previ-
ous malaria experiences, respectively) (Table 2)
Association between IL4-590 polymorphism and anti-P. 
falciparum IgG subclasses and IgE antibody levels
The anti -P. falciparum -IgG1, -IgG2, -IgG3 and IgE anti-
body concentrations in relation to IL4-590 genotypes in
complicated malaria (CM) and uncomplicated malaria
(UCM) patients are illustrated in Table 3. In complicated
malaria, the levels of anti-P. falciparum IgG3 were signifi-
cantly different among individuals carrying IL4-590 TT,
CT and CC genotypes (P = 0.031), while the levels of anti-
P. falciparum IgG1 tended to be significant among IL4-590
genotype (P = 0.095). To study the impact between IL4-
590 genotypes on anti-P. falciparum IgG1 and IgG3 levels,
the antibody levels in individuals carrying different geno-
types were compared by TT to CT, TT to CC and CT to CC
genotypes. As shown in Table 4, the anti-P. falciparum
IgG1 levels were significantly different between individu-
als carrying TT genotype compared to those carrying CC
genotype (median 18.04 vs  223.80:  P  = 0.025) and
between individuals carrying CT genotype compared to
those carrying CC genotype (median 24.12 vs 223.80, P =
0.037). In contrast, the anti-P.falciparum IgG3 levels were
significantly different only between individuals carrying
TT compared to those carrying CT genotype (median 0.51
vs 1.20, P = 0.030). When complicated malaria patients
with or without previous malaria experiences (CME and
CMN, respectively) were analysed separately, similar pat-
terns were seen by the anti-P. falciparum IgG1 levels were
significantly different between individuals carrying TTMalaria Journal 2009, 8:286 http://www.malariajournal.com/content/8/1/286
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Agec(range) 25.0 (14-67) 24.0 (13-65) 0.849
Sex (male/female) 75/35 133/36 0.137
Nationalityd
Burmese 17 (15.5) 24 (14.2) 0.614
Karen 18 (16.4) 27 (16.0)
Mon 37 (33.6) 72 (42.6)
Thai 38 (34.5) 45 (26.6)
Laos 0 1 (0.6)
Blood groupsd
A 21 (19.1) 27 (16.0) 0.556
AB 6 (5.5) 7 (4.1)
B 34 (30.9) 58 (34.3)
O 47 (42.7) 66 (39.1)
NR 2 (1.8) 11 (6.5)
Haemoglobin variants*d
Hb variants 14 (12.7) 29 (17.2) 0.825
Normal 95 (86.4) 133 (78.7)
NR 1 (0.9) 7 (4.1)
G6PD deficiencyd
Deficiency 13 (11.8) 14 (8.3) 0.597
Normal 96 (87.3) 153 (90.5)
NR 1 (0.9) 2 (1.2)
Parasitaemiae (range) 117 322 (33-1 336 900) 5641 (17-238 800) <0.0001
Highest fever°Cf 38.1 ± 1.005 38.4 ± 0.981 0.011
Haemoglobin g/df 11.4 ± 0.24 12.1 ± 0.17 0.021
Creatinine mg/dlf 1.36 ± 1.21 0.88 ± 0.37 <0.0001
Glucose nmol/lf 131.47 ± 62.06 118.17 ± 28.78 0.016
Splenomegalyg
Positive 18 (16.4) 3 (1.8) 0.039
Negative 92 (83.4) 166 (98.2)
Hepatomegalyg
Positive 66 (60) 32 (18.9) < 0.0001
Negative 44 (40) 137 (81.1)
Previous malaria episodesd
Yes 30 (27.3) 93 (55.0) < 0.0004
No 78 (70.9) 76 (45)
NR 2 (1.8) 0
a = Number of patients, b = Mann Whitney U or unpaired t test used for the analysis, c = Median, d = Percentages (in the parenthesis), e = 
Geometric mean/ml of blood, f = Mean ± SD, g = Percentages of individual with enlarged spleens and/or liver are in the parenthesis. *The 
Hemoglobin (Hb) variants includes HbE, HbF. NR = No report.Malaria Journal 2009, 8:286 http://www.malariajournal.com/content/8/1/286
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and CC genotypes (median 8.54 vs 223.80: P = 0.002) as
well as between CT and CC genotypes (median 13.94 vs
223.80: P = 0.004). Interestingly, these observations were
seen only in complicated malaria patients without previ-
ous malaria experiences. While the difference in anti-P.
falciparum IgG3 levels between patients carrying TT and
CT genotype tended to be significant in complicated
malaria patients with previous malaria experiences
(median 1.32 vs 5.62: P = 0.075). No such tendency could
be observed in the levels of anti-P. falciparum IgG2 and IgE
in complicated malaria patients either with or without
previous malaria experiences. Among uncomplicated
malaria patients carrying TT, CT or CC genotypes, the lev-
els of anti-P. falciparum-IgG1, -IgG2, -IgG3 and IgE did not
differ.
To investigate whether the anti-P. falciparum IgG sub-
classes and IgE were associated with certain IL4-590 geno-
types and whether the distribution of the C and/or T allele
differed between patients with complicated and uncom-
plicated malaria either with low or high specific antibody
levels, the antibody profiles were divided into three tiles,
i.e. those with low, medium and high antibody levels.
This division was based on the findings that there was a
great individual variation in antibody responses to the
crude plasmodium antigens. Because of the low numbers
of homozygotes for the IL4-590 C allele frequency, the
individuals homozygous and heterozygous for C alleles
(CC+CT) were pooled and compared with those
homozygous for T alleles. In complicated malaria, indi-
viduals homozygous for T alleles had significantly lower
anti-P. falciparum IgG3 antibody (P = 0.0054), while no
significant difference was found in uncomplicated
malaria (P = 0.079). Conversely, the IL4-590 genotypes
were not significantly associated either with anti-P. falci-
parum -IgG1, -IgG2 or with anti-P. falciparum IgE antibod-
ies when low and high tiles in complicated and
uncomplicated malaria were compared (Table 5). When
the results were analysed separately according to the his-
tory of individual's malaria experiences, only individuals
homozygous for T alleles had significantly lower anti-P.
falciparum IgG3 antibody in complicated malaria patients
with previous malaria experiences (CME) (P = 0.0156)
while higher anti-P. falciparum IgG3 antibody levels were
seen in uncomplicated malaria patients with previous
malaria experiences (UCME) (P = 0.0206). In contrast, no
such associations could be found when the IL4-590 geno-
types were compared between complicated malaria
patients without previous malaria experiences (CMN) and
uncomplicated malaria patients. Conversely, high anti-P.
falciparum IgG1 antibody levels seem to be associated with
the  IL4-590TT genotype in uncomplicated malaria
patients with previous malaria experiences (UCME) (P =
0.1219) (Table 6). No significant associations between
IL4-590 genotypes and anti-P. falciparum IgG2 and IgE
antibodies were found when the low and the high tiles
Table 2: Allele and genotype frequencies of IL4-590 
polymorphism in complicated and uncomplicated malaria 
patients with or without previous malaria experiences.
IL4-590 C/T Genotype n (%) Allele %
CC CT CC C T
CME 2 (7.4) 11 (40.7) 14 (51.9) 27.78 72.22
UCME 7 (7.7) 33 (36.2) 51 (56.0) 25.82 74.18
P-value# 0.9137 0.7501
CMN 4 (5.3) 34 (44.7) 38 (50.0) 27.63 72.37
UCMN 4 (5.4) 35 (47.3) 35 (47.3) 29.05 70.95
P-value 0.9459 0.8755
#Chi- squared test was used for the analysis
Table 3: Anti-P. falciparum IgG subclass and IgE levels (median) separated by IL4-590 CT genotype in patients with complicated and 
uncomplicated malaria (CM, UCM).
CC CT TT
N Median N Median N Median P-value#
CM
Anti-PfIgG1* 5 223.80 46 24.12 53 18.04 0.096
Anti-PfIgG2* 5 6.05 46 2.03 53 2.79 0.112
Anti-PfIgG3* 5 1.51 46 1.20 53 1.52 0.031
Anti-PfIgE** 5 0.43 47 0.62 53 2.36 0.915
UCM
Anti-PfIgG1* 11 252.80 67 39.32 84 88.21 0.195
Anti-PfI g G 2 * 1 1 7 . 6 06 84 . 4 08 35 . 7 7 0 . 2 9 9
Anti-PfI g G 3 * 1 1 2 . 6 56 82 . 6 98 53 . 1 3 0 . 6 2 2
Anti-PfI g E * * 1 1 0 . 9 66 80 . 6 58 50 . 7 6 0 . 8 9 2
* = μg/ml, ** = ng/ml, N = number of patients, #Statistical analysis of differences
in IgG subclass levels among the different genotypes tested with ANOVA.Malaria Journal 2009, 8:286 http://www.malariajournal.com/content/8/1/286
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were compared in all CME, CMN, UCME and UCMN
(uncomplicated malaria patients without previous
malaria experiences)
Discussion
This study demonstrated that IL4-590 genotypes could
differently regulate anti-P. falciparum -IgG1 and -IgG3
responses. The association between individuals
homozygous for IL4-590 T alleles and the levels of anti-P.
falciparum IgG3 was found only in patients who had pre-
vious malaria experiences with low levels in complicated
malaria and high levels in uncomplicated malaria. When
the differences in antibody levels between genotypes were
explored, similar results were seen for anti-P. falciparum
IgG3 in that complicated malaria patients with previous
malaria experiences tended to have lower IgG3 levels in
those carrying TT compared to CT genotypes. In contrast,
the complicated malaria patients without previous
malaria experiences who carried CC genotype had signifi-
cantly higher IgG1 than those carrying either CT or TT
genotypes. Thus, repeated exposure and host genetics, i.e
the polymorphism of IL4-590 or other related genes has
an impact on the modulation of antibody isotype profiles
and altered clinical outcome.
The relationship between IL4 polymorphism and anti-P.
falciparum  IgG subclasses antibody levels has not been
studied thoroughly. This is the first finding to show that a
single nucleotide polymorphism at position IL4-590 tran-
sition from C to T is associated with the levels of anti-P.
falciparum IgG3 antibody in malaria patients. In compli-
cated malaria especially those with previous malaria expe-
riences, the levels of anti-P. falciparum IgG3 were
significantly different among patients carrying IL4-590
CC, CT or TT genotypes. In particular, complicated
malaria patients homozygous for IL4-590 T alleles and
with previous malaria experiences exhibited significantly
lower levels of anti-P. falciparum IgG3 antibody than their
IL4-590 counterparts, whereas significantly higher levels
were found in uncomplicated malaria patients
homozygous for IL4-590 T alleles and with previous
malaria experiences. Similar trends were observed for the
anti-P. falciparum IgG1 in uncomplicated malaria patients
with previous malaria experiences although this did not
reach statistically significant differences. These results are
consistent with the previous findings that low levels of
IgG3 may lead to the onset of complicated malaria while
high IgG3 antibody levels may protect against malaria
[25,26] and with the demonstration on the induction of
CD40L stimulated naïve B cells by IL4 alone or in combi-
nation with IL10 to express IgG1, IgG2 and IgG3, but little
IgG4 [27]. IgG3 can activate the complement pathways
[28] and co-operate through FcR receptors [29], thus,
IgG3 could induce cell mediated lysis via complement
pathways, phagocytosis and/or ADCI mechanism [2,30]
which are all known to facilitate parasite clearance. In fact,
IgG3 may involve in anti-disease immunity by neutraliz-
ing parasite toxin, the glycosylphosphatidylinositol (GPI)
membrane anchors of P. falciparum surface proteins and/
or inhibiting cytoadherence of infected red blood cells,
thus, interfering the parasite sequestration [31,32]. In
humans, IL10, IL21 are associated with IgG1 and IgG3
antibody production [7,8,33] while IL-27 is modest and
regulates exclusively the production of IgG1 [34]. Further-
more, the interaction and combination of different base
changes at several sites in the promoter and/or the co-
localized alleles of these cytokines and their signaling
genes including the IL4-590 polymorphism may differ in
patients with complicated and uncomplicated malaria
and thus, alter the IgG1 and IgG3 production. This may
Table 4: Anti-P. falciparum IgG1 and IgG3 levels (median) 
according to IL4-590 genotypes in complicated malaria patients 
with or without previous malaria experiences.
CM
CC (5)a CT (46)a TT (53)a P-value#
Anti-PfIgG1* - 24.12 18.04 0.628
223.80 - 18.04 0.025
223.80 24.12 - 0.037
Anti-PfIgG3* - 1.20 0.51 0.030
1.51 - 0.51 0.159
1.51 1.20 - 0.455
CME
CC (2) CT (11) TT (14) P-value
Anti-PfIgG1* - 31.13 53.04 0.983
280.43 - 0.835
280.43 31.13 53.04 0.830
Anti-PfIgG3* - 5.62 1.32 0.075
8.06 - 1.32 0.384
8.06 5.62 - 0.961
CMN
CC (3) CT (33) TT (38) P-value
Anti-PfIgG1* - 13.94 8.54 0.636
223.80 - 8.54 0.002
223.80 13.94 - 0.004
Anti-PfIgG3* - 0.80 0.40 0.217
1.51 - 0.40 0.154
1.51 0.80 - 0.274
* = μg/ml, #Statistical analysis of differences in IgG subclass levels
between the different genotypes tested with unpaired t-test,
a = Number of patients (in the parenthesis).Malaria Journal 2009, 8:286 http://www.malariajournal.com/content/8/1/286
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also explain why different anti-P. falciparum IgG3 levels
were observed only among patients with complicated
malaria carrying IL4-590 TT genotype compared to their
counterparts.
The present study did not reveal any association between
IL4-590 C/T transition and the severity of malaria in either
with or without previous malaria experiences, although
there was an association between IL4-590 TT genotype
and the levels of anti-P. falciparum IgG3 antibody in both
complicated and uncomplicated malaria patients with
previous malaria experiences. The reason for this discrep-
ancy is probably due to: firstly, the polymorphism itself
may not be functional but act as genetic markers of other
functional polymorphisms; secondly, the polymorphisms
may directly regulate IL4 production only in the presence
of other genetic determinants. In contrast to the results
recently demonstrated in Mali of West Africa. The IL4-590
T alleles were associated with the increased levels of both
total and anti-malarial IgE in the Fulani, but not the
Dogon. However, IL4-590 polymorphism did not influ-
ence on the levels of anti-malarial IgG1-3 subclasses in
both the Fulani and the Dogon [35]. The reason for
genetic disparities can be attributed to different ages, eth-
nicity, geographical differences, and clinical feature as
asymptomatic and acute malaria infection.
The IL4-590 C or T alleles in association with primary and
secondary anti-P. falciparum -IgG1 and -IgG3 responses
were different. The IL4-590 T allele was associated with
anti-P. falciparum IgG3 levels in which the low levels were
observed in complicated and the high levels were
observed in uncomplicated malaria with previous malaria
experiences. In complicated malaria with previous
malaria experiences, the anti-P. falciparum IgG3 levels
tended to be lower in patients carrying TT than those car-
rying CT genotypes. Conversely, the IL4-590 T allele
seems to be associated with high anti-P. falciparum IgG1 in
only uncomplicated malaria patients with previous
malaria experiences, whereas, complicated malaria
patients without previous malaria experiences who car-
ried CC genotype had significantly higher anti-P. falci-
parum IgG1 than those either with CT or TT genotypes.
Therefore, it is likely that T allele associated with second-
ary malaria infection, while C allele associated with pri-
mary infection. The shift of Ig-isotypes from primary to
secondary responses has been demonstrated in mouse
models to be correlated with the levels of either Th1 or
Th2 cytokines [17]. Th1 subset predominates in the non-
specific primary response, whereas Th2 is the major acti-
vated pathway in the secondary specific response. As dem-
onstrate earlier that the nuclear factor of activated T cells
(NFAT) binding site at IL4-590 T creates a hair trigger for
Table 5: Association between IL4-590 genotype and anti-P. falciparum -IgG1, -IgG2, -IgG3 and IgE low or high tiled levels in patients 
with complicated and uncomplicated malaria.
Complicated Uncomplicated
3-tiles of Ig levels N CC CT TT P-value# CC CT TT P-value#
Anti-Pf IgG1 274 5A 46B 53C 11A 67B 84C
Anti-Pf IgG2 274 5 46 53 11 68 83
Anti-Pf IgG3 276 5 46 53 11 68 85
Anti-Pf IgE 277 5 47 53 11 68 85
Anti-PfIgG1* Low 0-14.47 91D 02 0 2 6 0 . 3 9 5 2 2 31 6 0 . 1 1 8
Medium 14.76-106.1 92 2 16 16 3 20 32
High 107.2-1874 91 3 10 11 6 24 36
Anti-PfIgG2* Low 0.414-2.384 91 0 26 23 0.856 2 23 17 0.179
Medium 2.386-6.617 92 3 12 22 3 19 29
High 6.629-177 91 2 8 8 6 26 37
Anti-PfIgG3* Low 0.053-0.798 92 1 19 30 0.0054 3 20 16 0.079
Medium 0.854-3.55 92 2 13 18 5 22 28
High 3.629-119 92 21 45 3 2 64 1
Anti-Pf IgE** Low 0.015-0.3851 92 2 15 17 0.896 3 28 25 0.564
Medium 0.3854-1.332 93 2 17 21 4 14 30
High 1.346-29.05 92 1 15 15 4 26 30
N = Number of plasma for determining IgG1, IgG2, IgG3, IgE and genotyping IL4-590, # = Chi-squared test was used to test the difference of IL4-
590 CC+CT and TT distribution between the low and high 3 tiles. * = μg/ml, ** = ng/ml, A = number of patients who carry IL4-590 CC genotype, 
B = number of patients who carry IL4-590 CT genotype, C = number of patients who carry IL4-590 TT genotype, D = Number of patients who had 
low, middle and high anti-P. falciparum -IgG1, -IgG2, -IgG3 and IgE levels.Malaria Journal 2009, 8:286 http://www.malariajournal.com/content/8/1/286
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IL4 transcription, it is advantageous when a Th2 response
is required, while IL4-590 C is favored when a Th1
response is required [36]. Therefore, the modulation of
Th1 and Th2 cytokines productions could have the impact
on antibody classes and subclasses productions. It is pos-
sible that IL4-590°C or T in combination with previous
exposure to malaria antigens probably partly modify the
antibody isotype profiles and thus represent a wide spec-
trum of clinical symptoms. However, some of these obser-
vations need to be confirmed in a larger sample size in
order to correct the confounding factors, such as age,
number of previous episodes and parasite-virulence.
Conclusion
This study showed that IL4-590 C or T is likely to play a
modulating role in the regulation of antibody profiles in
primary and secondary immune responses. The IL4-590 T
allele participated in the regulation of anti-P. falciparum -
IgG1 and -IgG3 in secondary infection, whereas IL4-590 C
allele might participated in the regulation of anti-P. falci-
parum IgG1 in primary infection. In individuals carrying
the IL4-590 TT genotype with previous malaria experi-
ences, an increased risk of complicated malaria was asso-
ciated with low anti-P. falciparum IgG3 antibody, whereas
a lower risk was associated with high antibody levels.
However, a panel of genetic variations in humoral
immune responses and their related genes in larger sam-
ple size should be further investigated which may provide
clue for better understanding in the alteration of disease
severity.
List of abbreviations used
CM: complicated malaria patients; CME: complicated
malaria patients with previous malaria experiences; CMN:
complicated malaria patients without previous malaria
experiences; UCM: uncomplicated malaria patients;
UCME: uncomplicated malaria patients with previous
malaria experiences; UCMN: uncomplicated malaria
patients without previous malaria experiences.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
SK and PT designed the study; PT prepared the blood sam-
ples, performed the IL4-590 genotyping and ELISA, col-
Table 6: Association between IL4-590 genotype and anti-P. falciparum -IgG1 and -IgG3 levels base on previous experiences malaria 
infection in patients with complicated and uncomplicated malaria.
Complicated malaria
Without previous malaria experiences (76)a With previous malaria experiences (27)
3-tiles of Ig levels CC CT TT P-value# CC CT TT P-value#
Anti-PfIgG1* Low 0-14.47 0A 17B 21C 0.1373 0 3 4 0.7715
Medium 14.76-106.1 1 11 11 1 4 5
High 107.2-1874 2 5 6 1 4 5
Anti-PfIgG3* Low 0.053-0.798 0 17 23 0.2136 1260 . 0 1 5 6
Medium 0.854-3.55 2 10 11 0 2 7
High 3.629-119 1 6 4 171
Uncomplicated malaria
Without previous malaria experiences (74) With previous malaria experiences (91)
CC CT TT P-value# CC CT TT P-value#
Anti-PfIgG1 Low 0-14.47 0 15 11 0.8019 2750 . 1 2 1 9
Medium 14.76-106.1 2 9 12 1 11 20
High 107.2-1874 2 11 11 41 3 2 5
Anti-PfIgG3 Low 0.053-0.798 1 13 12 0.8772 2740 . 0 2 0 6
Medium 0.854-3.55 1 10 12 4 11 16
High 3.629-119 2 12 11 11 4 3 0
a = Number of patients (in the parenthesis), # = Chi- squared test was used to test the difference of IL4-590 CC, CT and TT distribution between 
the low and high 3 tiles, * = μg/ml, A, B and C = number of patients with previous malaria experiences for determining anti-P. falciparum -IgG1, -
IgG3 and carry IL4-590 CC, CT, TT genotypes, respectively.Malaria Journal 2009, 8:286 http://www.malariajournal.com/content/8/1/286
Page 9 of 10
(page number not for citation purposes)
lected clinical data, analysed statistics and drafted the
manuscript; HP contributed to ELISA; MH assisted in IL4-
590 genotyping; SK and MTB supervised the work, revised
the manuscript and financed the research. All authors read
and approved the final manuscript.
Acknowledgements
We wish to acknowledge the contribution of Late Professor Sornchai 
Looareesuwan, Department of Clinical Tropical Medicine and the Hospital 
for Tropical Diseases, Faculty of Tropical Medicine, Mahidol University in 
providing blood samples and clinical data and his staff for their assistance in 
blood collection. We thank all patients for their kind participation in the 
study and Margareta Hagstedt, Stockholm University for her technical 
assistance. This study was supported by The Royal Golden Jubilee Ph.D. 
Programme (5 MMU44A1), the Basic Research Grant for the Royal Golden 
Jubilee Ph.D. (BGJ4580004) of the Thailand Research Fund (TRF), the 
Swedish Foundation for International Cooperation in Research and Higher 
Education (STINT), the Swedish International Development Co-operation 
Agency (SIDA/SAREC), the BioMalPar EU, #LSHP-CT-2004, 503578, Fac-
ulty of Tropical Medicine, Mahidol University and the Faculty of Medicine, 
Srinakharinwirot University. The present study was approved by the Ethical 
Committee of Faculty of Tropical Medicine, Mahidol University.
References
1. Perlmann P, Perlmann H, Looareesuwan S, Krudsood S, Kano S, Mat-
sumoto Y, Brittenham G, Troye-Blomberg M, Aikawa M: Contrast-
ing functions of IgG and IgE antimalarial antibodies in
uncomplicated and severe Plasmodium falciparum malaria.
Am J Trop Med Hyg 2000, 62:373-377.
2. Bouharoun-Tayoun H, Druilhe P: Plasmodium falciparum malaria:
evidence for an isotype imbalance which may be responsible
for delayed acquisition of protective immunity.  Infect Immun
1992, 60:1473-1481.
3. Bereczky S, Montgomery SM, Troye-Blomberg M, Rooth I, Shaw MA,
Farnert A: Elevated anti-malarial IgE in asymptomatic individ-
uals is associated with reduced risk for subsequent clinical
malaria.  Int J Parasitol 2004, 34:935-942.
4. Cerutti A, Zan H, Schaffer A, Bergsagel L, Harindranath N, Max EE,
Casali P: CD40 ligand and appropriate cytokines induce
switching to IgG, IgA, and IgE and coordinated germinal
center and plasmacytoid phenotypic differentiation in a
human monoclonal IgM+IgD+ B cell line.  J Immunol 1998,
160:2145-2157.
5. Cerutti A, Zan H, Kim EC, Shah S, Schattner EJ, Schaffer A, Casali P:
Ongoing in vivo immunoglobulin class switch DNA recombi-
nation in chronic lymphocytic leukemia B cells.  J Immunol
2002, 169:6594-6603.
6. Fear DJ, McCloskey N, O'Connor B, Felsenfeld G, Gould HJ: Tran-
scription of Ig germline genes in single human B cells and the
role of cytokines in isotype determination.  J Immunol 2004,
173:4529-4538.
7. Malisan F, Briere F, Bridon JM, Harindranath N, Mills FC, Max EE,
Banchereau J, Martinez-Valdez H: Interleukin-10 induces immu-
noglobulin G isotype switch recombination in human CD40-
activated naive B lymphocytes.  J Exp Med 1996, 183:937-947.
8. Fujieda S, Saxon A, Zhang K: Direct evidence that gamma 1 and
gamma 3 switching in human B cells is interleukin-10
dependent.  Mol Immunol 1996, 33:1335-1343.
9. Jeannin P, Lecoanet S, Delneste Y, Gauchat JF, Bonnefoy JY: IgE ver-
sus IgG4 production can be differentially regulated by IL-10.
J Immunol 1998, 160:3555-3561.
10. Kawano Y, Noma T, Yata J: Regulation of human IgG subclass
production by cytokines. IFN-gamma and IL-6 act antagonis-
tically in the induction of human IgG1 but additively in the
induction of IgG2.  J Immunol 1994, 153:4948-4958.
11. Kondo N, Inoue R, Kasahara K, Fukao T, Kaneko H, Tashita H, Ter-
amoto T: Reduced expression of the interferon-gamma mes-
senger RNA in IgG2 deficiency.  Scand J Immunol 1997,
45:227-230.
12. Rosenwasser LJ, Klemm DJ, Dresback JK, Inamura H, Mascali JJ, Klin-
nert M, Borish L: Promoter polymorphisms in the chromo-
some 5 gene cluster in asthma and atopy.  Clin Exp Allergy 1995,
25(Suppl 2):74-78. discussion 95-76
13. Nakashima H, Miyake K, Inoue Y, Shimizu S, Akahoshi M, Tanaka Y,
Otsuka T, Harada M: Association between IL-4 genotype and
IL-4 production in the Japanese population.  Genes Immun 2002,
3:107-109.
14. Luoni G, Verra F, Arca B, Sirima BS, Troye-Blomberg M, Coluzzi M,
Kwiatkowski D, Modiano D: Antimalarial antibody levels and
IL4 polymorphism in the Fulani of West Africa.  Genes Immun
2001, 2:411-414.
15. Verra F, Luoni G, Calissano C, Troye-Blomberg M, Perlmann P, Perl-
mann H, Arca B, Sirima BS, Konate A, Coluzzi M, Kwiatkowski D,
Modiano D: IL4-589C/T polymorphism and IgE levels in
severe malaria.  Acta Trop 2004, 90:205-209.
16. Gyan BA, Goka B, Cvetkovic JT, Kurtzhals JL, Adabayeri V, Perlmann
H, Lefvert AK, Akanmori BD, Troye-Blomberg M: Allelic polymor-
phisms in the repeat and promoter regions of the inter-
leukin-4 gene and malaria severity in Ghanaian children.  Clin
Exp Immunol 2004, 138:145-150.
17. D'Imperio Lima MR, Alvarez JM, Furtado GC, Kipnis TL, Coutinho A,
Minoprio P: Ig-isotype patterns of primary and secondary B
cell responses to Plasmodium chabaudi chabaudi correlate
with IFN-gamma and IL-4 cytokine production with CD45RB
expression by CD4+ spleen cells.  Scand J Immunol 1996,
43:263-270.
18. Tangteerawatana P, Pichyangkul S, Hayano M, Kalambaheti T,
Looareesuwan S, Troye-Blomberg M, Khusmith S: Relative levels of
IL4 and IFN-gamma in complicated malaria: association with
IL4 polymorphism and peripheral parasitemia.  Acta Trop 2007,
101:258-265.
19. Tangteerawatana P, Montgomery SM, Perlmann H, Looareesuwan S,
Troye-Blomberg M, Khusmith S: Differential regulation of IgG
subclasses and IgE antimalarial antibody responses in com-
plicated and uncomplicated Plasmodium falciparum malaria.
Parasite Immunol 2007, 29:475-483.
20. Singhasivanon P, Kidson C, Supavej S, eds: Mekong Malaria II:
update of malaria, multi-drug resistance and economic
development in the Mekong region of Southeast Asia.  South-
east Asia J Trop Med and Pub Health 2003, 34(suppl 4):63-68.
21. World Health Organization: Severe and complicated malaria.
Trans R Soc Trop Med Hyg 2000, 94(Suppl):51-90.
22. Troye-Blomberg M, Perlmann H, Patarroyo M, Perlmann P: Regula-
tion of the immune response in Plasmodium falciparum
malaria. II. Antigen specific proliferative responses in vitro.
Clin Exp Immunol 1983, 53:345-353.
23. Perlmann H, Helmby H, Hagstedt M, Carlson J, Larsson P, Troye-
Blomberg M, Perlmann P: IgE anti-malarial antibodies in Plasmo-
dium falciparum malaria: association of high IgE levels with
cerebral malaria.  Clin Exp Immunol 1994, 97:284-292.
24. Alloueche A, Silveira H, Conway DJ, Bojang K, Doherty T, Cohen J,
Pinder M, Greenwood BM: High-throughput sequence typing of
T-cell epitope polymorphisms in Plasmodium falciparum cir-
cumsporozoite protein.  Mol Biochem Parasitol 2000, 106:273-282.
25. Metzger WG, Okenu DM, Cavanagh DR, Robinson JV, Bojang KA,
Weiss HA, McBride JS, Greenwood BM, Conway DJ: Serum IgG3
to the Plasmodium falciparum merozoite surface protein 2 is
strongly associated with a reduced prospective risk of
malaria.  Parasite Immunol 2003, 25:307-312.
26. Sarthou JL, Angel G, Aribot G, Rogier C, Dieye A, Toure Balde A,
Diatta B, Seignot P, Roussilhon C: Prognostic value of anti-Plas-
modium falciparum-specific immunoglobulin G3, cytokines,
and their soluble receptors in West African patients with
severe malaria.  Infect Immun 1997, 65:3271-3276.
27. Tangye SG, Ferguson A, Avery DT, Ma CS, Hodgkin PD: Isotype
switching by human B cells is division-associated and regu-
lated by cytokines.  J Immunol 2002, 169:4298-4306.
28. Burton DR, Gregory L, Jefferis R: Aspects of the molecular struc-
ture of IgG subclasses.  Monogr Allergy 1986, 19:7-35.
29. Groux H, Gysin J: Opsonization as an effector mechanism in
human protection against asexual blood stages of Plasmo-
dium falciparum: functional role of IgG subclasses.  Res Immunol
1990, 141:529-542.
30. Tebo AE, Kremsner PG, Luty AJ: Plasmodium falciparum: a major
role for IgG3 in antibody-dependent monocyte-mediatedPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Malaria Journal 2009, 8:286 http://www.malariajournal.com/content/8/1/286
Page 10 of 10
(page number not for citation purposes)
cellular inhibition of parasite growth in vitro.  Exp Parasitol
2001, 98:20-28.
31. Boutlis CS, Fagan PK, Gowda DC, Lagog M, Mgone CS, Bockarie MJ,
Anstey NM: Immunoglobulin G (IgG) responses to Plasmo-
dium falciparum glycosylphosphatidylinositols are short-lived
and predominantly of the IgG3 subclass.  J Infect Dis 2003,
187:862-865.
32. Schofield L, Mueller I: Clinical immunity to malaria.  Curr Mol Med
2006, 6:205-221.
33. Mewono L, Matondo Maya DW, Matsiegui PB, Agnandji ST, Kendjo E,
Barondi F, Issifou S, Kremsner PG, Mavoungou E: Interleukin-21 is
associated with IgG1 and IgG3 antibodies to erythrocyte-
binding antigen-175 peptide 4 of Plasmodium falciparum in
Gabonese children with acute falciparum malaria.  Eur
Cytokine Netw 2008, 19:30-36.
34. Boumendjel A, Tawk L, Malefijt RW, Boulay V, Yssel H, Pene J: IL-27
induces the production of IgG1 by human B cells.  Eur Cytokine
Netw 2006, 17:281-289.
35. Vafa M, Maiga B, Israelsson E, Dolo A, Doumbo OK, Troye-Blomberg
M: Impact of the IL-4 -590 C/T transition on the levels of Plas-
modium falciparum specific IgE, IgG, IgG subclasses and total
IgE in two sympatric ethnic groups living in Mali.  Microbes
Infect 2009, 11:779-784.
36. Rockman MV, Hahn MW, Soranzo N, Goldstein DB, Wray GA: Pos-
itive selection on a human- specific transcription factor bind-
ing site regulating IL4 expression.  Curr Biol 2003, 13:2118-2123.